Management of Thrombocytopenia and Elevated INR
In a patient with platelet count of 70,000/µL and elevated PT/INR who is not actively bleeding and not undergoing invasive procedures, no prophylactic transfusion of platelets or fresh frozen plasma is indicated.
Clinical Context Assessment
The decision to administer blood products depends critically on three factors:
- Presence of active bleeding 1
- Planned invasive procedures or surgery 1
- Underlying etiology (hypoproliferative vs. consumptive thrombocytopenia) 1, 2
Platelet Management
For Non-Bleeding Patients
A platelet count of 70,000/µL does NOT require prophylactic platelet transfusion in the absence of bleeding or planned procedures 1, 2. The Surviving Sepsis Campaign guidelines clearly state that prophylactic platelet transfusion should only occur when counts are <10,000/mm³ in the absence of bleeding, or <20,000/mm³ if significant bleeding risk exists 1.
Procedure-Based Thresholds
If invasive procedures are planned, transfusion thresholds vary 1, 2:
- Low-risk procedures (e.g., central venous catheter in compressible sites): Transfuse if platelets <10,000/µL 2
- Lumbar puncture: Transfuse if platelets <20,000/µL 2
- Interventional radiology low-risk procedures: Transfuse if platelets <20,000/µL 2
- Major surgery or high-risk procedures: Transfuse if platelets <50,000/µL 1, 2
- Active bleeding: Target platelet count ≥50,000/mm³ 1
Special Considerations
For patients with platelet dysfunction (e.g., on antiplatelet agents like clopidogrel), transfusion may be indicated despite adequate platelet counts if there is excessive bleeding 1.
In consumptive thrombocytopenia (e.g., immune thrombocytopenic purpura, heparin-induced thrombocytopenia), prophylactic platelet transfusion is ineffective and rarely indicated 1.
Fresh Frozen Plasma (FFP) Management
For Non-Bleeding Patients with Elevated INR
Fresh frozen plasma should NOT be used to correct laboratory clotting abnormalities in the absence of bleeding or planned invasive procedures 1. This is a clear recommendation from the Surviving Sepsis Campaign guidelines.
Indications for FFP Transfusion
FFP is indicated only in specific circumstances 1:
- Active microvascular bleeding with PT >1.5 times normal OR INR >2.0, OR aPTT >2 times normal 1
- Urgent reversal of warfarin therapy (use 5-8 mL/kg FFP, or preferably prothrombin complex concentrate with vitamin K) 1
- Massive hemorrhage when coagulation tests cannot be obtained timely and patient has received >1 blood volume replacement 1
- Before invasive procedures in patients with significant coagulopathy 1
Dosing When Indicated
When FFP is necessary, administer 10-15 mL/kg to achieve minimum 30% plasma factor concentration 1. For urgent warfarin reversal, 5-8 mL/kg usually suffices 1.
Warfarin Reversal (If Applicable)
If the elevated INR is due to warfarin and requires reversal 1:
- Non-severe bleeding: Oral or IV vitamin K (2.5-10 mg) 1
- Severe/life-threatening bleeding: 4-factor prothrombin complex concentrate (PCC) PLUS vitamin K 1
Common Pitfalls to Avoid
- Do not transfuse based solely on laboratory values without clinical context 1, 2
- Verify the INR elevation is real - certain medications (e.g., daptomycin) and laboratory errors can cause falsely elevated INR 3, 4
- Consider the underlying cause - consumptive coagulopathies may not respond to simple replacement therapy 1
- In massive hemorrhage, anticipate coagulopathy and use early FFP to prevent dilutional coagulopathy rather than waiting for laboratory confirmation 1
- Monitor fibrinogen levels in bleeding patients, as fibrinogen <1.0 g/L (ideally maintain >1.5 g/L) indicates need for cryoprecipitate 1
Monitoring Recommendations
For patients with abnormal coagulation parameters 1: